BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG - News) today announced it filed a Citizen Petition1 with the U.S. Food and Drug Administration (FDA) regarding the proper application of product licensure and labeling standards for follow-on topical thrombin products. The petition also raises specific issues concerning the application of these standards to a biologics license application (BLA) filed by ZymoGenetics for a recombinant topical thrombin product which is currently under review by the FDA.
